Department of Neurology and Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland
Zurich, Zurich, Switzerland
My Name is Manuela Silginer and I obtained my PhD degree in neurooncological research in 2013 investigating the significance of integrin inhibition as a novel strategy to inhibit TGF-β-mediated processes in gliomas (Roth et al., 2013; Silginer et al., 2014; Silginer et al., 2016) in the Laboratory of Molecular Neuro-Oncology in Zurich led by Prof. Michael Weller. Subsequently, I started my post-doctoral position and was involved in several research projects investigating other novel therapeutic approaches against gliomas (Silginer et al., 2017a; Silginer et al., 2017b; Neidert et al., 2018; Weiss et al., 2018; Papachristodoulou et al., 2019a; Weiss et al., 2020) as well as mechanisms of therapy resistance (Happold et al., 2012; Happold et al., 2014; Happold et al., 2018). In May 2018, I was appointed as the head of this laboratory and this position allows independent research activity. My specific research topic is that of immunosuppression in glioblastoma mediated by programmed death ligand 1 and transforming growth factor beta.
